.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

AJMC® in the Press, October 6, 2017

Published on: October 6, 2017

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The National Pharmaceutical Council’s Daily Newsfeed e-mail on Monday highlighted a product theater published by The American Journal of Managed Care^® (AJMC^®). The article, “Experts Present Evidence and Advice on Canagliflozin,” discussed the presentation of the CANVAS and CANVAS-R trials at the 77th Scientific Sessions of the American Diabetes Association in San Diego, California, on June 12, 2017. The trials found that canagliflozin, a type 2 diabetes therapy, was linked to a 14% reduction in the combined endpoint of nonfatal heart attacks, nonfatal strokes, and cardiovascular death.